SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues. [Read more…]
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.
Toulouse, 2026 April 16th – Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China
Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillment
FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China’s biopharmaceutical and advanced therapy community. Under the agreement, MineBio will distribute RoosterBio’s full platform of research-grade and CliniControlTM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControlTM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay. [Read more…]
AABB Releases New Exam Prep Bundles For its Certified Advanced Biotherapies Professional (CABP) Credentialing Program
April 1, 2026, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the launch of two new exam prep bundles for its Certified Advanced Biotherapies Professional (CABP) credentialing program: the CABP Exam Prep Complete Bundle and the CABP Exam Prep Core Bundle. The new bundles are designed to help candidates prepare for AABB’s CABP exam. [Read more…]
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing
Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.
Archimedes® One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 21
- Next Page »